echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > $87 million! Think Di Pharmaceuticals is exclusively licensed by the next generation of dual-specific antibodies in Greater China

    $87 million! Think Di Pharmaceuticals is exclusively licensed by the next generation of dual-specific antibodies in Greater China

    • Last Update: 2021-01-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Today (January 5), 3D Pharmaceuticals (3D Pharmaceuticals) announced a cooperation agreement with Y-Biologics, a South Korean biotech company, to obtain exclusive development, production and commercial rights for the latter's dual-specific antibody YBL-013 in Greater China, and will jointly develop the product worldwide.
    YBL-013 is a new dual-specific antibody drug based on Y-Biologics' unique Antipodean Like Cell Engager (ALiCE) platform that can act on both CD3 subjects of T cells and PD-L1 of tumor cells.
    it is known that the technology is genetically engineered on the traditional antibody structure to have a unique 2:1 structure, including two targeted tumor antigen Fab region and a specific target T cell cd3 receptor Fv region, specifically activated tumor exosome T cells.
    this technique, can greatly reduce the current T-cell dual-specific antibodies may have toxic side effects.
    Under the terms of the agreement, Y-Biologics will be responsible for the development costs of the YBL-013 portion of IND and will receive a $2 million contract and be eligible for additional development, registration, commercialization and sales milestone payments of up to $85 million, as well as licensing fees of up to double-digit net sales in the authorized region.
    YBL-013 will receive exclusive development, production and commercial rights in Greater China, as well as joint development or priority rights for YBL-013 in other regions of the world.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.